Approach: Anti-fibrotic
Funding Impact: Accelerated identification of lead compound and de-risked pre-clinical program


Approach: Anti-inflammatory, anti-osteoporosis, potential steroid sparing therapies
Funding Impact: Industry partnership to sponsor clinical trial for Duchenne

Capricor Therapeutics

Approach: Cardiac stem cell derived therapy
Funding Impact: Initiation of Phase 1/2 study (HOPE Clinical Trial)
Successful Exit: Stock Return

Bamboo Therapeutics

Approach: Gene therapy for Duchenne
Funding Impact: Accelerated vector manufacturing capabilities
Successful Exit: Acquired by Pfizer in August 2016